Compare RAIL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | BDSX |
|---|---|---|
| Founded | 1901 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.9M | 122.0M |
| IPO Year | 2005 | 2020 |
| Metric | RAIL | BDSX |
|---|---|---|
| Price | $9.20 | $12.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 153.2K | 57.7K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $500,991,000.00 | $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.70 |
| P/E Ratio | $8.63 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $5.26 | $0.25 |
| 52 Week High | $14.90 | $20.21 |
| Indicator | RAIL | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 39.56 |
| Support Level | $9.00 | $6.00 |
| Resistance Level | $10.18 | $12.70 |
| Average True Range (ATR) | 0.41 | 1.04 |
| MACD | 0.30 | -0.36 |
| Stochastic Oscillator | 84.62 | 13.20 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.